These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 21205967)

  • 1. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
    Fabbri M; Bottoni A; Shimizu M; Spizzo R; Nicoloso MS; Rossi S; Barbarotto E; Cimmino A; Adair B; Wojcik SE; Valeri N; Calore F; Sampath D; Fanini F; Vannini I; Musuraca G; Dell'Aquila M; Alder H; Davuluri RV; Rassenti LZ; Negrini M; Nakamura T; Amadori D; Kay NE; Rai KR; Keating MJ; Kipps TJ; Calin GA; Croce CM
    JAMA; 2011 Jan; 305(1):59-67. PubMed ID: 21205967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A large fraction of trisomy 12, 17p
    Pepe F; Rassenti LZ; Pekarsky Y; Labanowska J; Nakamura T; Nigita G; Kipps TJ; Balatti V; Croce CM
    Proc Natl Acad Sci U S A; 2022 Jan; 119(4):. PubMed ID: 35064090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia.
    Deneberg S; Kanduri M; Ali D; Bengtzen S; Karimi M; Qu Y; Kimby E; Mansouri L; Rosenquist R; Lennartsson A; Lehmann S
    Epigenetics; 2014 Jun; 9(6):910-7. PubMed ID: 24686393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-34a as part of the resistance network in chronic lymphocytic leukemia.
    Zenz T; Mohr J; Eldering E; Kater AP; Bühler A; Kienle D; Winkler D; Dürig J; van Oers MH; Mertens D; Döhner H; Stilgenbauer S
    Blood; 2009 Apr; 113(16):3801-8. PubMed ID: 18941118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
    Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS
    Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Karyotype-specific microRNA signature in chronic lymphocytic leukemia.
    Visone R; Rassenti LZ; Veronese A; Taccioli C; Costinean S; Aguda BD; Volinia S; Ferracin M; Palatini J; Balatti V; Alder H; Negrini M; Kipps TJ; Croce CM
    Blood; 2009 Oct; 114(18):3872-9. PubMed ID: 19717645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of miR-15/16 in CLL.
    Pekarsky Y; Croce CM
    Cell Death Differ; 2015 Jan; 22(1):6-11. PubMed ID: 24971479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
    Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
    Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.
    Balatti V; Rizzotto L; Miller C; Palamarchuk A; Fadda P; Pandolfo R; Rassenti LZ; Hertlein E; Ruppert AS; Lozanski A; Lozanski G; Kipps TJ; Byrd JC; Croce CM; Pekarsky Y
    Proc Natl Acad Sci U S A; 2015 Feb; 112(7):2169-74. PubMed ID: 25646413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis.
    Greipp PT; Smoley SA; Viswanatha DS; Frederick LS; Rabe KG; Sharma RG; Slager SL; Van Dyke DL; Shanafelt TD; Tschumper RC; Zent CS
    Br J Haematol; 2013 Nov; 163(3):326-33. PubMed ID: 24032430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the molecular pathogenesis of chronic lymphocytic leukemia: dissecting a microRNA regulatory network.
    Allendorf DJ; Davis RS
    JAMA; 2011 Jan; 305(1):95-7. PubMed ID: 21205973
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
    Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A
    Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications.
    Dierlamm J; Michaux L; Criel A; Wlodarska I; Van den Berghe H; Hossfeld DK
    Cancer Genet Cytogenet; 1997 Mar; 94(1):27-35. PubMed ID: 9078288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.
    Pekarsky Y; Santanam U; Cimmino A; Palamarchuk A; Efanov A; Maximov V; Volinia S; Alder H; Liu CG; Rassenti L; Calin GA; Hagan JP; Kipps T; Croce CM
    Cancer Res; 2006 Dec; 66(24):11590-3. PubMed ID: 17178851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.
    Kienle DL; Korz C; Hosch B; Benner A; Mertens D; Habermann A; Kröber A; Jäger U; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2005 Jun; 23(16):3780-92. PubMed ID: 15867199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interphase fluorescence in situ hybridization analysis of del(11)(q23) and del(17)(p13) in chronic lymphocytic leukemia. a study of 40 early-onset patients.
    Doneda L; Montillo M; Intropido L; Tedeschi A; Morra E; Larizza L
    Cancer Genet Cytogenet; 2003 Jan; 140(1):31-6. PubMed ID: 12550755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.
    Mohr J; Helfrich H; Fuge M; Eldering E; Bühler A; Winkler D; Volden M; Kater AP; Mertens D; Te Raa D; Döhner H; Stilgenbauer S; Zenz T
    Blood; 2011 Feb; 117(5):1622-32. PubMed ID: 21115975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia.
    Wang LQ; Kwong YL; Wong KF; Kho CS; Jin DY; Tse E; Rosèn A; Chim CS
    J Transl Med; 2014 Feb; 12():52. PubMed ID: 24559316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.